Literature DB >> 25965356

Immune response regulation in the tumor microenvironment by hypoxia.

Sara Labiano1, Asis Palazon2, Ignacio Melero3.   

Abstract

Lymphocytes and myeloid cells sense hypoxia by the hypoxia-inducible factor (HIF) transcriptional system and via other molecular mechanisms. Low O2 availability is a hallmark of most solid tumors in which infiltrating leukocytes experience severe hypoxia once away from nurturing blood vessels. HIF controls migration, differentiation, and effector functions on immune cells. Importantly, in the tumor microenvironment the hypoxia response modulates the expression levels for important molecular targets in immunotherapy such as CD137, OX-40, FOXP3, and PD-L1. Modulation by hypoxia of tumor-associated macrophages, myeloid-derived suppressor cells, and dendritic cells ought to play an important underexplored role in modulating tumor immunity. Overall, low O2 seems to invigorate some anti-tumor effector T-cell functions while conflictingly favoring T-regulatory cells (Tregs) in terms of their differentiation, suppressive functions, and recruitment. Hypoxia also has been shown to uphold myeloid cell-mediated tumor-promoting inflammation and the immunosuppressive functions of tumor-associated macrophages. Detailed research of this intricate and poorly understood balance is warranted to improve the outcome of cancer immunotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25965356     DOI: 10.1053/j.seminoncol.2015.02.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  45 in total

Review 1.  Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

Authors:  Sun Ha Choi; Seung Soo Yoo; Shin Yup Lee; Jae Yong Park
Journal:  Arch Pharm Res       Date:  2022-04-21       Impact factor: 4.946

Review 2.  Advanced Hepatocellular Cancer: the Current State of Future Research.

Authors:  Louise C Connell; James J Harding; Ghassan K Abou-Alfa
Journal:  Curr Treat Options Oncol       Date:  2016-08

Review 3.  Hypoxia and acidosis: immune suppressors and therapeutic targets.

Authors:  Sultan Damgaci; Arig Ibrahim-Hashim; Pedro M Enriquez-Navas; Shari Pilon-Thomas; Albert Guvenis; Robert J Gillies
Journal:  Immunology       Date:  2018-03-30       Impact factor: 7.397

Review 4.  Contribution of metabolic reprogramming to macrophage plasticity and function.

Authors:  Karim C El Kasmi; Kurt R Stenmark
Journal:  Semin Immunol       Date:  2015-10-09       Impact factor: 11.130

Review 5.  Regulation of immunity and inflammation by hypoxia in immunological niches.

Authors:  Cormac T Taylor; Sean P Colgan
Journal:  Nat Rev Immunol       Date:  2017-10-03       Impact factor: 53.106

6.  Glycididazole sodium combined with radioiodine therapy for patients with differentiated thyroid carcinoma (DTC).

Authors:  Qiang Wen; Qingjie Ma; Lin Bai; Tongtong Wang; Yuping Han; Haishan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.

Authors:  Sara Labiano; Florinda Meléndez-Rodríguez; Asís Palazón; Álvaro Teijeira; Saray Garasa; Iñaki Etxeberria; M Ángela Aznar; Alfonso R Sánchez-Paulete; Arantza Azpilikueta; Elixabet Bolaños; Carmen Molina; Hortensia de la Fuente; Patricia Maiso; Francisco Sánchez-Madrid; Manuel Ortiz de Landázuri; Julián Aragonés; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

8.  Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer.

Authors:  Xianchao Sun; Zhen Zhou; Ying Zhang; Jinyou Wang; Xiaofeng Zhao; Liang Jin; Tingshuai Zhai; Xiang Liu; Jiaxin Zhang; Wangli Mei; Bihui Zhang; Ming Luo; Xudong Yao; Lin Ye
Journal:  Cancer Cell Int       Date:  2021-05-07       Impact factor: 5.722

Review 9.  Hypoxia/HIF Modulates Immune Responses.

Authors:  Yuling Chen; Timo Gaber
Journal:  Biomedicines       Date:  2021-03-05

10.  Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.

Authors:  Nehal Gupta; Shreyas Gaikwad; Itishree Kaushik; Stephen E Wright; Maciej M Markiewski; Sanjay K Srivastava
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.